Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

PD-1 and its ligands are important immune checkpoints in cancer

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Application of PD-1 Blockade in Cancer Immunotherapy

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients

PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

A snapshot of the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type